SCHEMBL17186605

SCHEMBL17186605

N=C(NC(=O)N1CCCC1)N1CCCC1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.44
HTT P42858 2/20 0.42
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALOX15 P16050 1/20 0.39
POLB P06746 2/20 0.37
HSD11B1 P28845 1/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
F2 P00734 1/20 0.37
RAB9A P51151 4/20 0.36
NPC1 O15118 3/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15588635 0.82 F2 (0.46) HTTALDH1A1SMN1; SMN2ALOX15POLB
SCHEMBL5406500 0.82 GAA (0.52) GAAHTTALDH1A1SMN1; SMN2ALOX15
SCHEMBL15588798 0.79 F2 (0.50) GAAHTTALDH1A1SMN1; SMN2ALOX15
Hydrochloric Acid SCHEMBL15560657 0.79 F2 (0.43) ALDH1A1SMN1; SMN2ALOX15POLBMAPT
SCHEMBL15588799 0.79 F2 (0.50) GAAHTTALDH1A1SMN1; SMN2ALOX15
SCHEMBL17186639 0.79 F2 (0.46) GAAHTTALDH1A1POLBHSD11B1
SCHEMBL28492500 0.79 F2 (0.46) GAAHTTALDH1A1SMN1; SMN2ALOX15
SCHEMBL3260890 0.79 ALDH1A1 (0.42) GAAHTTALDH1A1POLBHSD11B1
SCHEMBL17336983 0.77 F2 (0.50) GAAHTTALDH1A1POLBHSD11B1
Hydrochloric Acid SCHEMBL18605189 0.77 F2 (0.44) GAAHTTALDH1A1POLBHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US claimed
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 EP disclosed
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 EP disclosed
US-11465989-B2 Guanidine compounds and use thereof ImmunoMet Therapeutics, Inc. (US) 2022-10-11 US disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US disclosed
EP-3131877-A1 GUANIDINE COMPOUNDS AND USE THEREOF Immunomet Therapeutics Inc. (US) 2017-02-22 EP disclosed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 WO disclosed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11465989-B2 Guanidine compounds and use thereof PC, TFAM, PCK2 GAA 604/4885HTT 399/4885ALDH1A1 1471/4885
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF PC, TFAM, PCK2 GAA 604/4885HTT 399/4885ALDH1A1 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.